JP7783164B2 - 改変インターロイキン２受容体ベータアゴニスト - Google Patents

改変インターロイキン２受容体ベータアゴニスト

Info

Publication number
JP7783164B2
JP7783164B2 JP2022509060A JP2022509060A JP7783164B2 JP 7783164 B2 JP7783164 B2 JP 7783164B2 JP 2022509060 A JP2022509060 A JP 2022509060A JP 2022509060 A JP2022509060 A JP 2022509060A JP 7783164 B2 JP7783164 B2 JP 7783164B2
Authority
JP
Japan
Prior art keywords
seq
modified
polypeptide
il2rβ
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544785A (ja
JP2022544785A5 (https=
Inventor
チェン，ヤン
ジャオ，ケーハオ
スワンソン，クリスティーナ
グエン，ジェナ
カレン，ネイサン
ハッサン，サミュエル・クレメント
ジアン，ニン
Original Assignee
エルピス・バイオファーマシューティカルズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルピス・バイオファーマシューティカルズ filed Critical エルピス・バイオファーマシューティカルズ
Publication of JP2022544785A publication Critical patent/JP2022544785A/ja
Publication of JP2022544785A5 publication Critical patent/JP2022544785A5/ja
Priority to JP2025203501A priority Critical patent/JP2026032136A/ja
Application granted granted Critical
Publication of JP7783164B2 publication Critical patent/JP7783164B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022509060A 2019-08-13 2020-08-13 改変インターロイキン２受容体ベータアゴニスト Active JP7783164B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203501A JP2026032136A (ja) 2019-08-13 2025-11-26 改変インターロイキン２受容体ベータアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886148P 2019-08-13 2019-08-13
US62/886,148 2019-08-13
PCT/US2020/046244 WO2021030633A1 (en) 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203501A Division JP2026032136A (ja) 2019-08-13 2025-11-26 改変インターロイキン２受容体ベータアゴニスト

Publications (3)

Publication Number Publication Date
JP2022544785A JP2022544785A (ja) 2022-10-21
JP2022544785A5 JP2022544785A5 (https=) 2023-08-22
JP7783164B2 true JP7783164B2 (ja) 2025-12-09

Family

ID=72243240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509060A Active JP7783164B2 (ja) 2019-08-13 2020-08-13 改変インターロイキン２受容体ベータアゴニスト
JP2025203501A Pending JP2026032136A (ja) 2019-08-13 2025-11-26 改変インターロイキン２受容体ベータアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203501A Pending JP2026032136A (ja) 2019-08-13 2025-11-26 改変インターロイキン２受容体ベータアゴニスト

Country Status (8)

Country Link
US (1) US20230002466A1 (https=)
EP (1) EP4013774A1 (https=)
JP (2) JP7783164B2 (https=)
KR (1) KR20220044534A (https=)
CN (1) CN114787182A (https=)
AU (1) AU2020329290A1 (https=)
CA (1) CA3147677A1 (https=)
WO (1) WO2021030633A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CA3169095A1 (en) * 2020-03-05 2021-09-10 Kenan Christopher GARCIA Designed il-2 variants
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
IL304365B2 (en) 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
CN113603791A (zh) * 2021-08-11 2021-11-05 厦门目青股权投资合伙企业(有限合伙) 一种融合蛋白及其应用
CN119731199A (zh) * 2022-05-10 2025-03-28 艾佩斯瑞生物制药公司 工程化的白细胞介素-2受体β降低结合的激动剂
WO2025010341A2 (en) * 2023-07-05 2025-01-09 The Trustees Of Dartmouth College Cytokine hybrid proteins and methods related thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119093A1 (en) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
JP2014502967A (ja) 2010-12-22 2014-02-06 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ インターロイキン２のスーパーアゴニストおよびアンタゴニスト

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
SG192673A1 (en) * 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
CN109535259A (zh) * 2012-12-05 2019-03-29 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
US11655452B2 (en) * 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
MX2021000801A (es) * 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502967A (ja) 2010-12-22 2014-02-06 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ インターロイキン２のスーパーアゴニストおよびアンタゴニスト
WO2012119093A1 (en) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARON M LEVIN; ET AL，EXPLOITING A NATURAL CONFORMATIONAL SWITCH TO ENGINEER AN INTERLEUKIN-2 ‘SUPERKINE’，NATURE，2012年03月25日，VOL:484, NR:7395，PAGE(S):529 - 533，http://dx.doi.org/10.1038/nature10975

Also Published As

Publication number Publication date
JP2026032136A (ja) 2026-02-25
WO2021030633A1 (en) 2021-02-18
JP2022544785A (ja) 2022-10-21
CA3147677A1 (en) 2021-02-18
AU2020329290A1 (en) 2022-03-24
CN114787182A (zh) 2022-07-22
US20230002466A1 (en) 2023-01-05
EP4013774A1 (en) 2022-06-22
KR20220044534A (ko) 2022-04-08

Similar Documents

Publication Publication Date Title
JP7783164B2 (ja) 改変インターロイキン２受容体ベータアゴニスト
JP7098725B2 (ja) 二重特異性２＋１コントースボディ
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
JP7148539B2 (ja) 免疫抱合体
JP2024045143A (ja) 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
JP6464255B2 (ja) 二重特異性ｔ細胞活性化抗原結合分子
JP2024138240A (ja) 新規の二重特異性アゴニスト４－１ｂｂ抗原結合分子
JP2023529981A (ja) 免疫活性化Ｆｃドメイン結合分子
US20230250152A1 (en) Ctla-4 variant immunomodulatory proteins and uses thereof
JP2021500902A (ja) 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
JP2019524053A (ja) Ｔｎｆファミリーリガンドトリマーとｐｄ１結合部分とを含む抗原結合分子
US20240067700A1 (en) T-cell modulatory polypeptides and methods of use thereof
US20240376171A1 (en) Protease-activated polypeptides
JP2023509952A (ja) 新規４－１ｂｂｌ三量体含有抗原結合分子
JP7815150B2 (ja) プロテアーゼ活性化型ｔ細胞二重特異性抗体
US20250326813A1 (en) Engineered interleukin-2 receptor beta reduced-binding agonist
HK40076453A (en) Engineered interleukin-2 receptor beta agonists
HK40103919A (zh) 蛋白酶活化的多肽
HK40078517A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251127

R150 Certificate of patent or registration of utility model

Ref document number: 7783164

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150